Well absorbed following oral administration
Undergoes significant first-pass metabolism to produce 5-carboxylic acid metabolite, designated as EXP3174.
This metabolite is a long-acting (6 to 8 hr), noncompetitive antagonist at the AT1 receptor and contributes to the pharmacological effects of Losartan.
This metabolite is 10-40 times more potent in blocking AT1 receptors than the original Losartan.
bioavailability is about 32%.